3 results match your criteria 513 oaps

  • Page 1 of 1

Early ADAMTS13 testing associates with pre-eclampsia occurrence in antiphospholipid syndrome.

Thromb Res 2021 07 27;203:101-109. Epub 2021 Apr 27.

Department of Gynaecology and Obstetrics, First Moscow State Medical University (Sechenov University), Russian Federation; Department of Haematology, CHU Nîmes, Univ Montpellier, Nîmes, France; Faculty of Pharmaceutical and Biological Sciences, Montpellier University, Montpellier, France; UA 011 INSERM- Université de Montpellier, Institut Desbrest d'Epidémiologie et de Santé Publique, Montpellier, France. Electronic address:

Introduction: Women with obstetric antiphospholipid syndrome (oAPS) still develop placental diseases, mainly pre-eclampsia (PEcl), which diagnosis is associated with reduced ADAMTS13 levels. Testing ADAMTS13 in newly pregnant oAPS may provide evidence for risk stratification.

Materials And Methods: We retrospectively investigated the prognostic value of ADAMTS13 activity, antigen and antibodies on stored plasma samples obtained prior to beginning low-molecular weight heparin-low dose aspirin treatment in 513 oAPS women. Read More

View Article and Full-Text PDF

Obstetric antiphospholipid syndrome: early variations of angiogenic factors are associated with adverse outcomes.

Haematologica 2017 05 25;102(5):835-842. Epub 2017 Jan 25.

Department of Hematology, University Hospital, Nîmes, France

The prognostic value of angiogenic factors in newly pregnant women with obstetric antiphospholipid syndrome (oAPS) has not been documented. We observed 513 oAPS who experienced three consecutive spontaneous abortions before the 10 week of gestation or one fetal loss at or beyond the 10 week. We assessed the plasma concentrations of the proangiogenic factor placenta growth factor (PIGF) and of the antiangiogenic factor soluble fms-like tyrosine kinase-1 on the eve and on the 4 day of the low-molecular weight heparin-low-dose aspirin treatment. Read More

View Article and Full-Text PDF

Basis and new developments in the field of oxazaphosphorines.

Cancer Invest 1988 ;6(5):513-32

Department of Cancer Research, ASTA PHARMA AG, Bielefeld, Federal Republic of Germany.

All the research results summarized herein were gained in the attempt to improve selectivity in cancer chemotherapy: "Chemotherapeutic agents are not only ends in themselves, they are also beginnings,. . . Read More

View Article and Full-Text PDF
  • Page 1 of 1